Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

0.5521
Delayed Data
As of Jul 22
 -0.0179 / -3.14%
Today’s Change
0.39
Today|||52-Week Range
5.60
-81.28%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$33.7M

Company Description

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla. The company was founded on March 9, 2010 and is headquartered in The Woodlands, TX.

Contact Information

Pernix Therapeutics Holdings, Inc.
10 North Park Place
Morristown New Jersey 07960
P:(800) 793-2145
Investor Relations:
180079321451009

Employees

Shareholders

Mutual fund holders8.90%
Other institutional48.02%
Individual stakeholders16.90%

Top Executives

John A. SedorChairman & Chief Executive Officer
Terence S. NovakChief Operating Officer
Sanjay S. PatelChief Financial Officer & Head-Investor Relations
Barry J. SiegelSenior Vice President & General Counsel
Michael GolembiewskiVice President-Finance & Corporate Controller